Did a Permissive Scientific Culture Encourage the ‘CRISPR babies’ experiment?
By Donna Dickenson, Marcy Darnovsky,
Nature Biotechnology
| 03. 15. 2019
To the Editor — The claim last November by He Jiankui to have engineered the first CRISPR-edited babies has ignited voluble condemnation from scientists worldwide. What, then, made this rogue researcher think that his ‘achievement’ would be welcomed? One possible factor is that He claimed that he was influenced by the words and actions of key US and UK scientists. He attended and was an invited speaker at several meetings about gene editing, including several focused on the ethical acceptability of human germline modification1. And he explicitly cited the 2017 US National Academies of Science report as support for what he did2.
The Nuffield Council on Bioethics in the UK also issued a report in July 20183. Notably, it concludes that germline genome editing could be permissible under certain circumstances. More strongly, it moves beyond the merely permissible to the ethically obligatory, saying in its final section (paragraph 5.2) that “there are moral reasons to continue with the present lines of research and to secure the conditions under which heritable genome editing would be...
Related Articles
By Mariella Bodemeier Loayza Careaga, The Scientist | 03.15.2024
Scientists have genetically modified isolated microbes for decades. Now, using CRISPR, they intend to target entire microbiomes.
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions of microscopic beings...
By Gerry Smith, Bloomberg | 03.12.2024
When Celenise Mahmood first learned about two new gene therapies that could cure sickle cell disease, she felt a wave of relief.
Her 9-year-old son, Navid, has the inherited blood disorder. By age 5, he’d had over 30 life-saving blood...
By Carol Cardona and Michelle Kromm, Scientific American | 03.11.2024
By Nada Hassanein, New Jersey Monitor | 03.14.2024
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...